Nora Therapeutics, a Palo Alto, CA-based biotechnology company focused on developing reproductive therapeutics, closed an $18m Series B financing.
The round was led by Novo A/S with participation from existing investors Burrill & Company, Prospect Venture Partners, Rho Ventures, and Vivo Capital. In conjunction with the financing, Heath Lukatch, Ph.D., Partner at Novo Ventures, will join Nora’s Board of Directors.
The company intends to use the funds to expand the development of its lead drug, NT100, including the addition of a second Phase 2 trial (RESPONSE) in women with unexplained recurrent pregnancy loss. NT100 is currently being studied in an ongoing Phase 2 trial (THRIVE-IVF).
Led by Jeffrey K. Tong, Ph.D., President and CEO, Nora Therapeutics focuses on developing therapeutics to address IVF failure and recurrent pregnancy loss. Its lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance.